Following on from information provided to NICE by the company in May 2016, the appraisal of Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 883

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 November 2022 Following on from information provided to NICE by the company in May 2016, the appraisal of Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
03 November 2022 Discontinued. Following on from information provided to NICE by the company in May 2016, the appraisal of Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
13 May 2016 Suspended. The Department of Health has asked the Institute to conduct an appraisal of rociletinib for previously treated locally advanced or metastatic, EGFR T790M -positive non-small-cell lung cancer. We have now been informed by the company that it will no longer be pursuing a licensing application , therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
22 March 2016 Draft scope documents
15 March 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual